Financials Advanced Oncotherapy plc
Equities
AVO
GB00BD6SX109
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.925 GBX | -.--% | +10.00% | +10.00% |
May. 09 | Advanced Oncotherapy Delists from London Bourse Amid Financing Deal | MT |
May. 03 | Advanced Oncotherapy financing talks continue, funds delayed | AN |
Valuation
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Capitalization 1 | 54.73 | 46.54 | 66.98 | 97.54 | 120 | 171.6 |
Enterprise Value (EV) 1 | 53.83 | 55.73 | 68.97 | 140.8 | 168.4 | 220.7 |
P/E ratio | -4.44 x | -3.28 x | -2.81 x | -4.07 x | -4.11 x | -4.93 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -4.22 x | -3.94 x | -3.22 x | -7.07 x | -8.74 x | -9.73 x |
EV / FCF | -2.93 x | -3.99 x | -3.01 x | -4.86 x | -7.47 x | -7.04 x |
FCF Yield | -34.1% | -25% | -33.2% | -20.6% | -13.4% | -14.2% |
Price to Book | 1.61 x | 1.62 x | 1.97 x | 2.28 x | 2.72 x | 2.8 x |
Nbr of stocks (in thousands) | 72,492 | 80,935 | 169,566 | 243,843 | 333,440 | 451,612 |
Reference price 2 | 0.7550 | 0.5750 | 0.3950 | 0.4000 | 0.3600 | 0.3800 |
Announcement Date | 6/26/17 | 6/28/18 | 6/28/19 | 6/29/20 | 6/30/21 | 6/30/22 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -12.74 | -14.13 | -21.39 | -19.93 | -19.27 | -22.69 |
EBIT 1 | -13.09 | -14.49 | -21.8 | -20.66 | -20.27 | -23.74 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -13.18 | -16.49 | -21.87 | -21.88 | -25.3 | -29.49 |
Net income 1 | -10.35 | -13.66 | -21.15 | -20.79 | -25.3 | -29.49 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.1702 | -0.1755 | -0.1405 | -0.0983 | -0.0875 | -0.0771 |
Free Cash Flow 1 | -18.36 | -13.95 | -22.91 | -28.96 | -22.55 | -31.36 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 6/26/17 | 6/28/18 | 6/28/19 | 6/29/20 | 6/30/21 | 6/30/22 |
Balance Sheet Analysis
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 9.19 | 1.99 | 43.3 | 48.3 | 49.1 |
Net Cash position 1 | 0.91 | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | -0.6506 x | -0.0929 x | -2.171 x | -2.507 x | -2.164 x |
Free Cash Flow 1 | -18.4 | -14 | -22.9 | -29 | -22.6 | -31.4 |
ROE (net income / shareholders' equity) | -33.8% | -43.6% | -67.4% | -54.1% | -58.1% | -55.9% |
ROA (Net income/ Total Assets) | -23.9% | -21.8% | -26% | -15.2% | -10.9% | -11.3% |
Assets 1 | 43.27 | 62.64 | 81.38 | 137.1 | 232.8 | 262 |
Book Value Per Share 2 | 0.4700 | 0.3500 | 0.2000 | 0.1800 | 0.1300 | 0.1400 |
Cash Flow per Share 2 | 0.0200 | 0 | 0.0100 | 0.0100 | 0.0100 | 0.0100 |
Capex 1 | 0.77 | 0.12 | 3.29 | 2.66 | 1.66 | 2.22 |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 6/26/17 | 6/28/18 | 6/28/19 | 6/29/20 | 6/30/21 | 6/30/22 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+10.00% | 11.88M | |
+11.73% | 226B | |
+9.53% | 188B | |
+14.63% | 137B | |
+27.47% | 108B | |
-0.04% | 63.19B | |
+13.73% | 52.26B | |
+4.86% | 51B | |
+7.72% | 43.89B | |
+7.86% | 38.07B |
- Stock Market
- Equities
- AVO Stock
- Financials Advanced Oncotherapy plc